About Broad Street Alerts:
Big Opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 534% in verifiable potential gains for our members on 3 small cap alerts alone!
January 31st, 2017 (NASDAQ: HIMX) opened at $5.10/share and hit a high of $9.68/share March 24th, 2017 for gains of 89% within 60 days-
February 6th, 2017- (NASDAQ: SCON) opened at $1.12/share hit a high of $1.80/share within 10 days our member potential gains- 60% –
March 6th, 2017 (OTC: USRM) opened at .035/share and hit over .17/share within 25 days for gains of 385% for our members-
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So, if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP – SMS/text alert service for free, simply text the word “Alerts” to the phone number “25827” from your cell phone.
Broad Street Alerts Mission Statement
We strive to highlight the future potential as well as the inherent risk in each small cap company we cover while remaining neutral as a leading third-party equity research firm. Please read our privacy policy and full disclaimer below.
CBIS Report:
Cannabis Science, Inc. has the advantage of unparalleled understanding of metabolic processes enabling it to provide innovative treatment options for medical needs, which are currently unmet.Cannabis has been used for thousands of years and currently there are many scientific publications, which provide evidence of the underlying effect on biochemical pathways. The company uses an innovative approach approach to discover to develop cannabinoid-based therapies to improve the lives of patients. It is dedicated to working closely with regulatory agencies to provide patients with access to high quality, first class cannabinoid pharmaceutical, especially for patients critically in need by using clinical trial material comes from the highest quality cultivation and production facilities. The products fall into the broad categories of medical cannabinoid formulations which are developed from one or more of the compounds extracted from the cannabis plant. The immediate focus is on the treatment of cancer which is one of the most important diseases globally .
In 2013, the company submitted a patent application in Europe, the subject of which is development of formulations based on cannabinoids to treat a range of neuro behavioural disorders. Cannabis plants have been extensively used in medical and agricultural applications for thousands of years. Some applications of cannabinoids include the used for the alleviation of nausea and the stimulation of appetite for patients suffering from AIDS and cancer. Other uses include the treatment of chronic pain and the reduction of muscle spasms caused by multiple sclerosis and injuries to the spinal cord. The company is long established in the use of cannabis.
The team of scientists at the company are focused on producing on commercialising products based on botanical extracts from cannabis as new uses continue to develop. For instance, scientists have recently discovered that topical preparations based on cannabinoids can be effective for treatment of MRSI, which is a deadly flesh eating disease resistant to antibiotics. Other topical applications are used to treat localised pain as in the treatment of arthritis and burns as well as neuropathic pain for which there are few effective alternative treatments. It is becoming increasingly evident that based on needs, which are self identified, around 2% of the Canadian adult population is already using cannabinoids for medicinal purposes and this is likely to become a multibillion dollar industry in the near future.
The investment potential
This pioneering biotech company has already created extract formulations based on cannabinoids for different medical conditions such as more than eight different types of cancer. Each of these formulations has the potential to bring in revenues and earnings in the hundreds and millions of dollars, especially when they are combined with NutraSweet fruit products and a strategic partnership with MedBox solutions. The market for cannabinoids is estimated at $ 30 billion-$ 50 billion and could be, according to internal estimates, has much as $ 75 billion, based on the Federal Medical Cannabis Program in 2017. This is the first publicly traded cannabinoid company involved in formulations based on cannabinoids extracts. The business model and leadership position could have plenty of investment business potential over the next couple of decades and the company could be potentially a billion-dollar biotech global leader. There could potentially be hundreds of millions of patients suffering from chronic pain, cancer, MS, PSTD and other terminal illnesses.
Recent developments
Crown Baus Capital Corp.(OTC PINK: CBCA), is a global conglomerate looking to capitalize on its key industry strengths. The team at the company are structuring investment opportunity with Cannabis Science for participation in a property and drug development project in Douglas County, Nevada. Cannabis Science has substantial property development contracts to build fully licensed facilities for cannabis and hemp production, which are fully state compliant and the investment opportunities are being divided into one acre parcels for each land development project. The objective is to build a portfolio of investors, partners and supply chain operators throughout the United States, which are in various stages of development. Cannabis Science has announced the beginning of a buildup of a cannabis drug development facility in Douglas County, Nevada, of which the first phase is approximately 33,000 ft.² of greenhouse space for every one acre plot. The first phase for each built out of one acre will cost between USD 300,000 and USD 500,000.
The bottom line
The company currently trades at a market valuation of around $ 280 million though it has little by way of assets or revenues and a rising short-term debt. However, the potential for this small cap stock is exciting for investors. The way has been prepared for the commercialisation of cannabis formulations without the necessity of the rigourous FDA approvals and the future could be promising. Though the company would require to use the normal procedures for producing a blockbuster pharmaceutical product, it is a cannabis company in right space and the stock could be a good way of playing the potential of the cannabis industry generally.
Broad Street Alerts has not been compensated for this report by anyone and the opinions if any are that of the author Ramakrishnan Iyar. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.